Zarepour Atefeh, Egil Abdurrahim Can, Cokol Cakmak Melike, Esmaeili Rad Monireh, Cetin Yuksel, Aydinlik Seyma, Ozaydin Ince Gozde, Zarrabi Ali
Biomedical Engineering Department, Faculty of Engineering & Natural Sciences, Istinye University, Istanbul 34396, Türkiye.
Faculty of Engineering and Natural Sciences, Materials Science and Nano-Engineering Program, Sabanci University, Istanbul 34956, Türkiye.
Polymers (Basel). 2023 Jan 6;15(2):298. doi: 10.3390/polym15020298.
Changes in weather conditions and lifestyle lead to an annual increase in the amount of lung cancer, and therefore it is one of the three most common types of cancer, making it important to find an appropriate treatment method. This research aims to introduce a new smart nano-drug delivery system with antibacterial and anticancer capabilities that could be applied for the treatment of lung cancer. It is composed of a niosomal carrier containing curcumin as an anticancer drug and is coated with a chitosan polymeric shell, alongside Rose Bengal (RB) as a photosensitizer with an antibacterial feature. The characterization results confirmed the successful fabrication of lipid-polymeric carriers with a size of nearly 80 nm and encapsulation efficiency of about 97% and 98% for curcumin and RB, respectively. It had the Korsmeyer-Peppas release pattern model with pH and temperature responsivity so that nearly 60% and 35% of RB and curcumin were released at 37 °C and pH 5.5. Moreover, it showed nearly 50% toxicity against lung cancer cells over 72 h and antibacterial activity against . Accordingly, this nanoformulation could be considered a candidate for the treatment of lung cancer; however, in vivo studies are needed for better confirmation.
天气条件和生活方式的变化导致肺癌发病率逐年上升，因此肺癌是最常见的三种癌症类型之一，找到合适的治疗方法至关重要。本研究旨在引入一种具有抗菌和抗癌能力的新型智能纳米药物递送系统，可用于肺癌治疗。它由含有姜黄素作为抗癌药物的囊泡载体组成，并包裹有壳聚糖聚合物外壳，同时还有具有抗菌特性的孟加拉玫瑰红（RB）作为光敏剂。表征结果证实成功制备了尺寸近80nm的脂质聚合物载体，姜黄素和RB的包封率分别约为97%和98%。它具有Korsmeyer-Peppas释放模式模型，对pH和温度有响应性，使得在37°C和pH 5.5时，近60%的RB和35%的姜黄素被释放。此外，在72小时内它对肺癌细胞显示出近50%的毒性，并对……具有抗菌活性。因此，这种纳米制剂可被视为肺癌治疗的候选药物；然而，需要进行体内研究以更好地证实。
